These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26384788)

  • 1. Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells.
    Singh A; Ruan Y; Tippett T; Narendran A
    J Exp Clin Cancer Res; 2015 Sep; 34(1):104. PubMed ID: 26384788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
    Zhang L; Xie D; Lei Y; Na A; Zhu L
    Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
    [No Abstract]   [Full Text] [Related]  

  • 3. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
    Zhang L; Scorsone K; Woodfield SE; Zage PE
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
    Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
    Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
    Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
    Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.
    Indini A; Tondini CA; Mandalà M
    Future Oncol; 2019 Mar; 15(9):967-977. PubMed ID: 30638071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.
    Eagles JR; Jimeno A
    Drugs Today (Barc); 2016 Nov; 52(11):593-605. PubMed ID: 28112278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted MEK inhibition by cobimetinib enhances doxorubicin's efficacy in osteosarcoma models.
    Ma L; Xu Y; Xu X
    Biochem Biophys Res Commun; 2020 Aug; 529(3):622-628. PubMed ID: 32736683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation.
    Shelake S; Eslin D; Sutphin RM; Sankpal UT; Wadwani A; Kenyon LE; Tabor-Simecka L; Bowman WP; Vishwanatha JK; Basha R
    Int J Dev Neurosci; 2015 Nov; 46():92-9. PubMed ID: 26287661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
    Lieu CH; Hidalgo M; Berlin JD; Ko AH; Cervantes A; LoRusso P; Gerber DE; Eder JP; Eckhardt SG; Kapp AV; Tsuhako A; McCall B; Pirzkall A; Uyei A; Tabernero J
    Oncologist; 2017 Sep; 22(9):1024-e89. PubMed ID: 28592615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
    Gong S; Xu D; Zhu J; Zou F; Peng R
    Cell Physiol Biochem; 2018; 47(2):680-693. PubMed ID: 29794421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
    BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation state affects morphine induced cell regulation in neuroblastoma cultured cells.
    Fiore G; Ghelardini C; Bruni G; Guarna M; Bianchi E
    Neurosci Lett; 2013 Oct; 555():51-6. PubMed ID: 23932892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.
    Sriraman SK; Geraldo V; Luther E; Degterev A; Torchilin V
    J Control Release; 2015 Dec; 220(Pt A):160-168. PubMed ID: 26497930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
    Luo P; Lin M; Li L; Yang B; He Q
    PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas.
    Kim S; Kang J; Hu W; Evers BM; Chung DH
    Int J Cancer; 2003 Jan; 103(3):352-9. PubMed ID: 12471618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells.
    Lee JH; Kim KT
    J Neurochem; 2004 Nov; 91(3):634-47. PubMed ID: 15485494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.